Conclusions: These updated results continue to support 50 mg of dasatinib daily as an effective and safe dose for newly diagnosed early CML-CP. https://pubmed.ncbi.nlm.nih.gov/31553487/ Article type: Clinical updateOriginal publication date: Friday, September 3, 2021 Log in or register to post comments